Stockscreener 앱 받기
24.90
1.54%
-0.41
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Piper Sandler reiterates Overweight rating on NewAmsterdam Pharma stock By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Overweight rating on NewAmsterdam Pharma stock - Investing.com
Bullish: Analysts Just Made A Meaningful Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Forecasts - Yahoo Finance
Analysts Are Upgrading NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) After Its Latest Results - Yahoo Finance
Can technical indicators confirm NewAmsterdam Pharma Company N.V.’s reversalEntry Opportunity Screener with Confirmation - Newser
Comparing NewAmsterdam Pharma Company N.V. Equity Warrant in custom built stock radarsFree Trade Setups With Clear Risk Limits - Newser
Visualizing NewAmsterdam Pharma Company N.V. Equity Warrant stock with heatmapsWeekly Price Target Forecast and Alerts - Newser
Visual analytics tools that track NewAmsterdam Pharma Company N.V. performanceFree Trade Setups With Clear Risk Limits - Newser
Technical analysis overview for NewAmsterdam Pharma Company N.V. stockFree AI Driven Buy Alert Trade Blueprint - Newser
Will NewAmsterdam Pharma Company N.V. price bounce be sustainableTechnical Reversal Setup with Risk Limits - Newser
NewAmsterdam Pharma Second Quarter 2025 Earnings: US$0.15 loss per share (vs US$0.41 loss in 2Q 2024) - uk.finance.yahoo.com
NewAmsterdam Pharma earnings beat by $0.35, revenue topped estimates - Investing.com UK
NewAmsterdam Pharma Reports Q2 2025 Financial Results - TipRanks
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% - The Motley Fool
Newamsterdam Pharma shares rise 6.12% intraday as Q2 net loss narrows and revenue rises. - AInvest
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
Newamsterdam Pharma shares rise 1.34% intraday as Q2 net loss narrows and revenue rises. - AInvest
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises - MarketScreener
NewAmsterdam Pharma Company NV reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q2 Revenue $19.1M, vs. FactSet Est of $1.9M - MarketScreener
Understanding NewAmsterdam Pharma Company N.V. Equity Warrant’s price movementFree Consistent Income Focused Trade List - Newser
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewswire
NewAmsterdam Pharma Co N.V. SEC 10-Q Report - TradingView
Is NewAmsterdam Pharma Company N.V. Equity Warrant the Top Chart Pick This WeekHigh Conviction Intraday Stock Signals Detected - beatles.ru
Published on: 2025-08-04 14:31:37 - metal.it
What is the dividend policy of NewAmsterdam Pharma Company N.V. stockInvest confidently with daily market forecasts - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. stock priceExponentially increasing returns - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. stock in 2025Discover stocks with massive upside potential - Jammu Links News
Is NewAmsterdam Pharma Company N.V. Equity Warrant a growth stock or a value stockTurn market volatility into profit opportunities - Jammu Links News
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V.Build a portfolio with strong long-term growth - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V.Accelerated wealth building - Jammu Links News
What institutional investors are buying NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Technical Analysis Support - Jammu Links News
Why is NewAmsterdam Pharma Company N.V. Equity Warrant stock attracting strong analyst attentionExceptional profit margins - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V. Equity WarrantBoost your returns with professional guidance - jammulinksnews.com
What is NewAmsterdam Pharma Company N.V. company’s growth strategyExceptional profit potential - Jammu Links News
What are NewAmsterdam Pharma Company N.V. Equity Warrant company’s key revenue driversCapitalize on emerging investment opportunities - Jammu Links News
What are NewAmsterdam Pharma Company N.V. company’s key revenue driversDiscover the fastest growing stocks today - Jammu Links News
Is it the right time to buy NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Stock Market Return Analysis - Jammu Links News
Published on: 2025-08-04 00:09:00 - Jammu Links News
When is NewAmsterdam Pharma Company N.V. stock expected to show significant growthStay ahead with daily market updates - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. Equity Warrant stock in 2025Game-changing returns - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceTap into rapid wealth building techniques - Jammu Links News
How strong is NewAmsterdam Pharma Company N.V. Equity Warrant company’s balance sheetCapitalize on market trends with expert guidance - Jammu Links News
Published on: 2025-08-03 11:05:58 - Jammu Links News
Published on: 2025-08-03 06:39:53 - Jammu Links News
What is the risk reward ratio of investing in NewAmsterdam Pharma Company N.V. Equity Warrant stockTurn market volatility into profit opportunities - Jammu Links News
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyInvest smarter with data-backed insights - Jammu Links News
What are analysts’ price targets for NewAmsterdam Pharma Company N.V. in the next 12 monthsPre Market Entry Points To Watch Now - Jammu Links News
Does NewAmsterdam Pharma Company N.V. qualify in momentum factor screeningReal-Time Analysis With Entry Targets In Progress - metal.it
1.52%
0.80%
자본화:
|
볼륨(24시간):